Page 1

BIG PureTech Health 2021 Half - Year Report August 24 , 2021 PURETECH GIVING LIFE TO SCIENCE® RNS Number : 5331J PureTech Health PLC 24 August 2021 24 August 2021 PureTech Health plc - Half - Year Report Strong capital base and cash runway expected into the first quarter of 2025 , with PureTech level cash and cash equivalents of $ 409.7 million¹ and consolidated cash and cash equivalents of $ 439.8 million² as of June 30 , 2021 Continued advancement of PureTech's Wholly Owned Programs , with two Phase 2 and four Phase 1 clinical trials underway and key preclinical data published in peer - reviewed journals for two of PureTech's four lymphatic and inflammation platforms Significant developments across the Founded Entities , Vor's Nasdaq listing , Gelesis ' merger agreement with Capstar SPAC to become publicly - traded , Karuna's progress with its Phase 3 program for KarXT in schizophrenia and Akili's scaled U.S. commercialization of EndeavorRxⓇ Company to host a webcast and conference call today at 9:00 am EDT / 2:00 pm BST PureTech Health plc ( Nasdaq : PRTC , LSE : PRTC ) ( " PureTech " or the " Company " ) today announces its half - yearly results for the six months ended June 30 , 2021. PureTech is a clinical - stage biotherapeutics company dedicated to discovering , developing and commercializing highly differentiated medicines for devastating diseases , including inflammatory , fibrotic and immunological conditions , intractable cancers , lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders , among others . The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists , clinicians and industry leaders . This pipeline , which is being advanced both internally and through PureTech's Founded Entities³ , is comprised of 25 therapeutics and therapeutic candidates , including 15 that are clinical stage and two that have received both U.S. Food and Drug Administration ( FDA ) clearance and European marketing authorization . The following information will be filed on Form 6 - K with the United States Securities and Exchange Commission and is also available at https://investors.puretechhealth.com/financials-filings/reports . 1. PureTech Level Cash and Cash equivalents as of June 30 , 2021 represent cash and cash equivalents held at PureTech Health plc and its wholly - owned subsidiaries only . Please refer to the Financial Review section of this report for additional detail . 2. Consolidated Cash and cash equivalents as of June 30 , 2021 represent cash and cash equivalents of $ 439.8 million as shown on the Consolidated Statements of Financial Position . 3. While PureTech maintains ownership of equity interests in its Founded Entities , the Company does not , in all cases , maintain control over these entities ( by virtue of ( i ) majority voting control and ( ii ) the right to elect representation to the entities ' boards of directors ) or direct the management and development efforts for these entities . Consequently , not all such entities are consolidated in the Company's financial statements . Where Pure Tech maintains control , the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements . Where Pure Tech does not maintain control , the entity is referred to as a Non - Controlled Founded Entity in this report and is not consolidated in the Company's financial statements . As of June 30 , 2021 , PureTech's Controlled Founded Entities included Follica Incorporated , Vedanta Biosciences , Inc. , Sonde Health , Inc. and Entrega , Inc. , and Pure Tech's Non - Controlled Founded Entities included Gelesis , Inc. , Karuna Therapeutics , Inc. , Akili Interactive Labs , Inc. and Vor Biopharma Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis ( as opposed to a voting basis ) as of June 30 , 2021 , including outstanding shares , options and warrants , but excluding unallocated shares authorized to be issued pursuant to equity incentive plans . Vedanta ownership was calculated on a diluted basis as of July 16 , 2021. For each of Karuna and Vor , ownership was calculated on an outstanding voting share basis as of June 30 , 2021 . Webcast and conference call details